Glioma Diagnosis and Treatment Market Research Report Information By Type (Primary Tumors and Secondary Tumors), By Diagnosis (Neurological Exam, CT Scan, MRI, PET Scan, Biopsy, Molecular Testing, EEG, and Others), By Treatment (Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, and Targeted Therapy), By Grade (Low Grade Glioma, High Grade Glioma, and Recurrent High Grade Glioma), By Location (Supratentorial and Infratentorial), By End User (Hospitals & Clinics, Diagnostic Centers, Medical Research Centers, and Others), and By Region

Global Glioma Diagnosis and Treatment Market Overview

Glioma Diagnosis and Treatment Market Size was valued at USD 3.2 Billion in 2022. The Glioma Diagnosis and Treatment market industry is projected to grow from USD 3.4 Billion in 2023 to USD 5.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.20% during the forecast period (2023 - 2032). Glioblastoma multiforme's rising prevalence, rising R&D, and advantageous regulatory conditions, are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Glioma Diagnosis and Treatment Market Trends

• The growing prevalence of glioblastoma multiforme is driving the market growth

The market is expected to rise as a result of a number of factors, including the rising prevalence of glioblastoma multiforme, increased R&D, and favourable regulatory environments. During the projected period, a robust pipeline is anticipated to play a significant role in driving the glioblastoma multiforme (GBM) therapy market. Over the course of the projection period, it is anticipated that the prevalence of brain tumours will spur market expansion. According to the  Cancer Observatory, there were 251,329 fatalities and 308,102 new cases of brain and CNS cancer worldwide in 2020. One of the most deadly types of cancer is brain cancer. The majority of malignant tumours, including up to 54% of gliomas and 16% of all primary brain malignancies, are glioblastomas multiforme. Adults are more likely than children to develop glioblastoma multiforme, and as people get older, their risk of doing so rises.

In the upcoming years, the market is anticipated to be driven by the rising acceptance of innovative therapies and combination therapies. For instance, the U.S. FDA authorised Pfizer's Zirabev, a biosimilar to Avastin, in June 2019 for the treatment of recurring cancers such as colorectal, NSCLC, and glioblastoma. The firm introduced its product in the United States in January 2020. Additionally, the U.S. FDA approved Samsung's BLA application for its SB8 bevacizumab biosimilar candidate in November 2019, increasing the likelihood that products may be released in the upcoming years.

Due to tumour heterogeneity and variation in treatment methods between patients, a customised treatment plan for glioblastoma multiforme is projected to become more necessary. It is projected that the acceptance of new treatments would increase patients with glioblastoma multiforme's life expectancy. Additionally, it is believed that the FDA's special designation of investigational drugs may speed up the approval and commercialization of novel therapeutics. For instance, the US FDA granted fast track designation to the Denovo biopharma medication DB102 (enzastaurin) in July 2020 for the treatment of patients who had recently been diagnosed with glioblastoma. Thus, driving the Glioma Diagnosis and Treatment market revenue.

Glioma Diagnosis and Treatment Market Segment Insights

Glioma Diagnosis and Treatment Type Insights

The Glioma Diagnosis and Treatment market segmentation, based on type, includes primary tumors and secondary tumors. Primary tumors segment dominated the market in 2022. This development is mostly related to the rising demand for primary tumour therapy.

Glioma Diagnosis and Treatment Diagnosis Insights

The Glioma Diagnosis and Treatment market segmentation, based on diagnosis, includes neurological exam, CT scan, MRI, PET scan, biopsy, molecular testing, EEG, and others. The neurological exam segment dominated the market in 2022. This is related to growing public knowledge of glioma diagnosis.

Glioma Diagnosis and Treatment Treatment Insights

The Glioma Diagnosis and Treatment market segmentation, based on treatment, includes surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. Radiation therapy segment dominated the market in 2022. This is because survival rates have increased. One treatment option is to combine radiation therapy with chemotherapy and surgery.

Glioma Diagnosis and Treatment Grade Insights

The Glioma Diagnosis and Treatment market segmentation, based on grade, includes low grade glioma, high grade glioma, and recurrent high-grade glioma. Low grade glioma segment dominated the Glioma Diagnosis and Treatment market in 2022. This can be related to adults developing low grade gliomas more frequently.

Glioma Diagnosis and Treatment Location Insights

The Glioma Diagnosis and Treatment market segmentation, based on location, includes supratentorial and infratentorial. Supratentorial segment dominated the Glioma Diagnosis and Treatment market in 2022. This is brought on by the increase in glioma prevalence in the supratentorial region.

Glioma Diagnosis and Treatment End User Insights

The Glioma Diagnosis and Treatment market segmentation, based on end user, includes hospitals & clinics, diagnostic centers, medical research centers, and others. The hospitals & clinics segment dominated the Glioma Diagnosis and Treatment market in 2022. This is because hospitals and dental clinics are increasingly preferred by people because they often offer all services using cutting-edge technology.

Figure 1 Glioma Diagnosis and Treatment Market, by End Users, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Glioma Diagnosis and Treatment Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Glioma Diagnosis and Treatment Market dominated this market in 2022 (45.80%). One of the main drivers of the regional market growth is government support for the growth of the healthcare industry, as well as high awareness of uncommon conditions, easy access to high-quality medical facilities, and kind reimbursement policies. Further, the U.S. Glioma Diagnosis and Treatment market held the largest market share, and the Canada Glioma Diagnosis and Treatment market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 GLIOMA DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Glioma Diagnosis and Treatment market accounted for the healthy market share in 2022. Large unmet needs in the market, rising awareness of GBM, and a strong pipeline of compounds with the capacity to cross the blood-brain barrier are a few of the major drivers of regional market expansion. Further, the German Glioma Diagnosis and Treatment market held the largest market share, and the U.K Glioma Diagnosis and Treatment market was the fastest growing market in the European region

The Asia Pacific Glioma Diagnosis and Treatment market is expected to register significant growth from 2023 to 2032. This is due to a number of causes, including the release of temozolomide generics, a stronger economy, an increase in the population of older people, and rising healthcare investment. Moreover, China’s Glioma Diagnosis and Treatment market held the largest market share, and the Indian Glioma Diagnosis and Treatment market was the fastest growing market in the Asia-Pacific region.

Glioma Diagnosis and Treatment Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Glioma Diagnosis and Treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Glioma Diagnosis and Treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Glioma Diagnosis and Treatment industry to benefit clients and increase the market sector. In recent years, the Glioma Diagnosis and Treatment industry has offered some of the most significant advantages to medicine. Major players in the Glioma Diagnosis and Treatment market, including Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc., Taj Pharmaceuticals Limited, Novartis International AG , Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals, LLC, Sun Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals. LLC, AstraZeneca, Carestream Health, and Hitachi Medical Corporation, are attempting to increase market demand by investing in research and development operations.

A biotechnology business in the development stage is Northwest Biotherapeutics Inc (NW Bio). It discovers and creates cancer immunotherapy products. The company creates potential therapeutic product candidates using its own unique technological platform, DCVax. A personalised immune therapy called DCVax uses the patient's own dendritic cells as the therapeutic agent in a therapeutic vaccination. The Paediatric Investigation Plan (PIP) for the Company was authorised by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) in August 2022.

A biotechnology business at the clinical stage is Diffusion Pharmaceuticals Inc. (Diffusion), formerly known as Diffusion Pharmaceuticals LLC. Standard of care therapies are developed. The business enhances chemotherapy and radiation therapy for solid tumours that are resistant to other forms of treatment, including several FDA-designated orphan indications. Diffusion Pharmaceuticals started a Phase II trial in July 2022 for people with glioblastoma multiforme that used cutting-edge imaging techniques to assess tumour oxygenation.

Key Companies in the Glioma Diagnosis and Treatment market include

• Thermo Fisher Scientific Inc.


• Emcure Pharmaceuticals Ltd.


• Sigma-Aldrich Co.


• Pfizer Inc.


• Taj Pharmaceuticals Limited


• Novartis International AG


• Teva Pharmaceutical Industries Ltd.


• GE Healthcare


• Siemens Healthineers


• Philips Healthcare


• Shimadzu Corporation


• Toshiba Medical Systems Corporation


• Merck & Co., Inc.


• Hoffmann-Le Roche AG


• Arbor Pharmaceuticals, LLC


• Sun Pharmaceutical Industries, Ltd.


• Amneal Pharmaceuticals. LLC


• AstraZeneca


• Carestream Health


• Hitachi Medical Corporation

Glioma Diagnosis and Treatment Industry Developments

April 2021 In order to treat glioblastoma multiforme, Lineage Cell Therapeutics and Immunomic Therapeutics engaged into a licencing agreement for the development of the allogeneic VAC cancer immunotherapy platform.

Glioma Diagnosis and Treatment Market Segmentation

Glioma Diagnosis and Treatment Type Outlook

• Primary Tumors


• Secondary Tumors

Glioma Diagnosis and Treatment Diagnosis Outlook

• Neurological Exam


• CT Scan


• MRI


• PET Scan


• Biopsy


• Molecular Testing


• EEG


• Others

Glioma Diagnosis and Treatment Treatment Outlook

• Surgery


• Chemotherapy


• Radiation Therapy


• Immunotherapy


• Targeted Therapy

Glioma Diagnosis and Treatment Grade Outlook

• Low Grade Glioma


• High Grade Glioma


• Recurrent High Grade Glioma

Glioma Diagnosis and Treatment Location Outlook

• Supratentorial


• Infratentorial

Glioma Diagnosis and Treatment End User Outlook

• Hospitals & Clinics


• Diagnostic Centers


• Medical Research Centers


• Others

Glioma Diagnosis and Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America